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c-Src is a tyrosine kinase belonging to the Src-family kinases (SFKs) which are a 
group of proteins involved in cancer development. Recently, c-Src has been reported 
to play an important role in the differentiation, cell-adhesion and survival of 
neuroblastoma (NB) cells [1]. NB is the most common extracranial pediatric solid 
tumor and usually undergoes rapid progression with a poor prognosis upon 
metastasis. Some of the pyrazolo[3,4-d]pyrimidine synthesized by our research group 
are c-Src inhibitors. In particular, compound SI306 (Figure) showed in vivo activity in a 
xenograft model using SH-SY5Y cells as well as optimal ADME characteristics [2]. With 
the aim of performing SAR (structure-activity relationship) studies, we synthesized a 
new library of SI306 analogues. Furthermore, in order to get further insights into the 
biological data, we tested this promising compound on the human MYCN-amplified 
neuroblastoma cell lines HTLA-230 and SK-N-BE-2C. In fact, amplification of MYCN, 
correlates with high-risk disease and poor prognosis [3]. The synthesis of the new 
derivatives and their biological results will be reported in the poster section. 
   
 Figure: Structure of SI306 
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